- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06800313
Een studie van HLD-0915 bij patiënten met metastatische castratieresistente prostaatkanker (MCRPC)
Fase 1/2 studie van HLD-0915 bij patiënten met metastatische castratie-resistente prostaatkanker (MCRPC)
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Study Contact
- Telefoonnummer: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Studie Locaties
-
-
-
Sutton, Verenigd Koninkrijk, SM2 5PT
- Werving
- The Royal Marsden NHS Trust
-
-
-
-
Colorado
-
Colorado Springs, Colorado, Verenigde Staten, 80909
- Werving
- Rocky Mountain Cancer Center
-
Denver, Colorado, Verenigde Staten, 80218
- Werving
- Sarah Cannon Research Institute 1
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06511
- Werving
- Yale University
-
-
Florida
-
Sarasota, Florida, Verenigde Staten, 34232
- Werving
- Florida Cancer Specialists
-
-
Louisiana
-
Metairie, Louisiana, Verenigde Staten, 70006
- Werving
- XCancer Research Network LCMC Health EJGH
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Werving
- Dana Farber Mass General Brigham Cancer Care Inc
-
-
Michigan
-
Grand Rapids, Michigan, Verenigde Staten, 49546
- Werving
- South Texas Accelerated Research Therapeutics, LLC (START)
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68130
- Werving
- Urology Cancer Center, PC
-
-
New York
-
Long Island City, New York, Verenigde Staten, 11101
- Werving
- Memorial Sloan Kettering Cancer Center
-
Syracuse, New York, Verenigde Staten, 13210
- Werving
- Associated Medical Professionals
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27710
- Werving
- Duke University Medical Center
-
-
South Carolina
-
Myrtle Beach, South Carolina, Verenigde Staten, 29572
- Werving
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- Sarah Cannon Research Institute
-
Nashville, Tennessee, Verenigde Staten, 37209
- Werving
- Urology Associates
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78758
- Werving
- NEXT Oncology
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- MD Anderson Cancer Center
-
-
Virginia
-
Norfolk, Virginia, Verenigde Staten, 23502
- Werving
- Virginia Clinical Research
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Patients must meet the following criteria to be eligible study participation:
Key Inclusion Criteria:
All Study Arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):
Males ≥ 18 years old Histological, pathological, and/or cytological confirmation of prostate adenocarcinoma Adequate hematological, renal, and hepatic function. Able to swallow oral medication
mCRPC Arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Prior orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testosterone Progressive mCRPC defined as having demonstrated PSA progression on the prior regimen
SOAR Arm (Phase 2 Part 2A) mHSPC with distant metastatic disease based on conventional imaging PSA ≥0.2 ng/mL, following treatment with next generation ARPI for at least 180 days and up to 365 days No evidence of radiographic or PSA progression while receiving ARPI
mHSPC arms (Phase 2 Part 2B, 2C & 2D) serum testosterone >150ng/ml mHSPC with distant metastatic disease based on conventional imaging and PSA >2.0 ng/mL
Key Exclusion Criteria:
All arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):
Has experienced a recent major bleed or has a known bleeding disorder Tumors exhibiting neuroendocrine or small cell carcinoma component by histopathology Receiving continuous corticosteroids at prednisone-equivalent dose of >10 mg/day Prior or ongoing significant medical condition
mCRPC arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Has received systemic anti-cancer therapy or investigational drugs within 2 weeks prior to first dose of study drug with certain exceptions requiring longer washout periods
SOAR arm (Phase 2 Part 2A) Has received any prior cytotoxic chemotherapy for prostate cancer
mHSPC arms (Phase 2 Part 2B, 2C & 2D) regional pelvic lymph node disease only
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: JNJ-101556143 Phase 1 Part 1 - Dose Escalation
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
Experimenteel: JNJ-101556143 Phase 1 Part 2 - Formulation Exploration
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 Experimental: Oral JNJ-101556143 Experimental: Oral JNJ-101556143 |
|
Experimenteel: JNJ-101556143 Phase 2 Part 1 - Dose Optimization
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
Experimenteel: Phase 2 Part 2A - SOAR
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
Experimenteel: Phase 2 Part 2B - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
Experimenteel: Phase 2 Part 2C - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
Experimenteel: Phase 2 Part 2D - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Frequency of dose-limiting toxicities (DLTs)
Tijdsspanne: 21 days
|
21 days
|
|
Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baseline
Tijdsspanne: 21 days
|
21 days
|
|
Phase 1 Part 2 (formulation exploration) relative bioavailability
Tijdsspanne: 22 days
|
22 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
PK Parameters
Tijdsspanne: 21 days
|
21 days
|
|
|
Duration of Response (DOR)
Tijdsspanne: 21 days
|
21 days
|
|
|
Radiographic Progression-Free Survival (rPFS)
Tijdsspanne: 63 days
|
63 days
|
|
|
Time to Response (TTR)
Tijdsspanne: 63 days
|
63 days
|
|
|
Change in PSA over time
Tijdsspanne: 21 days
|
Including PSA50 and PSA90 response |
21 days
|
|
Objective Response Rate (ORR)
Tijdsspanne: 63 days
|
Per RECIST in evaluable patients |
63 days
|
Medewerkers en onderzoekers
Onderzoekers
- Studie directeur: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- Prostaatkanker
- Prostaat Adenocarcinoom
- Prostaatneoplasmata
- Genitale neoplasmata, mannelijk
- Neoplasmata, glandulair en epitheel
- Genitale ziekten, man
- Gemetastaseerde castratieresistente prostaatkanker
- Urogenitale ziekten, man
- Riptac
- HLD-0915
- Urogenital Neoplasms, Male
- Hormone Sensitive, Castrate Resistant
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Neoplasmata per site
- Neoplasmata
- Prostaat Ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Neoplasmata per histologisch type
- Prostaatneoplasmata
- Neoplasmata, glandulair en epitheel
- Urogenitale neoplasmata
- Genitale neoplasmata, mannelijk
- Mannelijke urogenitale ziekten
- Genitale ziekten, man
Andere studie-ID-nummers
- HLD-0915-ONC-101
- HLD-0915-ONC-101 (Andere identificatie: Janssen Research & Development, LLC)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .